For the second quarter of the fiscal year ending March 2027, consolidated net sales increased by 158,276.0 million yen, operating income decreased by 12,902.9 million yen, ordinary income decreased by 14,380.0 million yen, and interim net income attributable to owners of the parent decreased by 8,240.0 million yen. Full-year forecast remains unchanged. Capital policy including share buyback continues, and the dividend is maintained at an annual 71 yen. By segment, pharmaceutical wholesale sales remained firm but profits were pressured by drug price revisions and higher logistics costs. Expansion of new investments and regenerative medicine-related businesses also continues.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2784","jir_company_name":"Alfresa Holdings Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/2784-20261109-01.pdf","jir_short_summary":"For the second quarter of the fiscal year ending March 2027, consolidated net sales increased by 158,276.0 million yen, operating income decreased by 12,902.9 million yen, ordinary income decreased by 14,380.0 million yen, and interim net income attributable to owners of the parent decreased by 8,240.0 million yen. Full-year forecast remains unchanged. Capital policy including share buyback continues, and the dividend is maintained at an annual 71 yen. By segment, pharmaceutical wholesale sales remained firm but profits were pressured by drug price revisions and higher logistics costs. Expansion of new investments and regenerative medicine-related businesses also continues.","jir_summary":"### Overview of Results\nAlfresa Holdings Corporation's consolidated results for the second quarter (interim period) of the fiscal year ending March 2027 recorded net sales of 1,582,760 million yen (a 3.5% increase year-on-year). However, operating income was 13,029 million yen (YoY -19.6%), ordinary income was 14,380 million yen (YoY -17.8%), and interim net income attributable to owners of the parent was 8,240 million yen (YoY -28.5%), representing declines. Factors affecting results include negative impacts from drug price revisions, increases in logistics and other costs, and startup expenses related to new drug development and capital expenditures. The full-year forecast remains unchanged, and recovery of performance will require balancing cost controls with growth investments. By segment, prescription pharmaceutical wholesale saw revenue growth, but manufacturing and logistics cost increases and drug price effects compressed profit margins.\n\n### Capital Policy and Outlook\nThe Company will continue share buybacks to improve capital efficiency. Treasury stock at the end of the interim period is approximately 35.9 hundred million yen, and the dividend forecast remains an annual 71 yen. The Company will continue to provide information to institutional investors through supplementary materials and briefings. The launch of new businesses in regenerative medicine and CRO areas continues, and efforts are underway to strengthen the business base in the Kyushu region and enhance cross-group strategic functions. In 2026, the Company realized business integrations through multiple consolidated subsidiaries and partnerships, and will continue to focus on integrated group-wide strengthening centered on TSCS.","jir_financial_highlights":"Net Sales: 1,582,760 (YoY 3.5% increase)\nOperating Income: 13,029 (YoY -19.6%)\nOrdinary Income: 14,380 (YoY -17.8%)\nNet Income Attributable to Owners of Parent (Interim): 8,240 (YoY -28.5%)\nTreasury Stock: 36,537 (At fiscal year-end)\nDividend: 35.00\uff0fshares (at second quarter-end) (Assumed consistent with results for the fiscal year ended March 2026)","jir_category":"","jir_hashtags":"#AlfresaHoldings, #Earnings, #Interim, #PharmaceuticalWholesale, #RegenerativeMedicine, #CapitalPolicy","jir_key_figures":"Net Sales: 1,582,760 million yen (YoY 3.5% increase)\nOperating Income: 13,029 million yen (YoY -19.6%)\nNet Income Attributable to Owners of Parent (Interim): 8,240 million yen (YoY -28.5%)","jir_meta_title":"Alfresa Holdings Corporation Financial Summary Q2 Interim\uff5cNet Sales Up, Profits Down","jir_meta_description":"Summary of Alfresa Holdings Corporation's Q2 interim results for the fiscal year ending March 2027. Net sales increased while operating income, ordinary income and net income declined. Covers segment trends, impacts of drug price revisions, rising costs, investments in regenerative medicine, and ongoing dividend and share buyback policy.","jir_og_title":"Alfresa Holdings Q2 Interim Results\uff5cNet Sales Up, Profits Down","jir_og_description":"The financial summary shows higher sales but lower profits due to drug price revisions and cost increases. Share buybacks and dividend policy are being maintained. Continued investment in regenerative medicine.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"[{label:'2025\/4-9',value:1529762},{label:'2026\/4-9',value:1582760}]\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"[{label:'2025\/4-9',value:16207},{label:'2026\/4-9',value:13029}]\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"[{segment:'Prescription Pharmaceutical Wholesale',value:14251},{segment:'Self-medication Wholesale',value:1305},{segment:'Pharmaceutical Manufacturing',value:238}]\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Margin Trend\", \"jir_chart_json_data\": \"[{label:'2025\/4-9',value:1.06},{label:'2026\/4-9',value:0.82}]\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"Comparison of Full-Year Forecast and Results\", \"jir_chart_json_data\": \"[{\u5e74\u5ea6:'2027',\u58f2\u4e0a\u9ad8\u4e88\u60f3:'3,144,000',\u5b9f\u7e3e:'1,582,760'}]\"}]","ir_related_company":7908,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-144736","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n